Inventor
Cen XU
Inventor
US
Overview
Patents· 6 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations22%
C07KPeptides22%
A61KPreparations for medical, dental or toiletry purposes19%
C12NMicroorganisms or enzymes15%
G01NInvestigating or analysing materials by determining their chemical or physical properties15%
Y02ATechnologies for adaptation to climate change7%
PatentTitleYear
12,134,652Human CGRP receptor binding proteins202412,122,841Human CGRP receptor binding proteins202411,919,964Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof202411,891,435Polynucleotides encoding monoclonal antibodies binding to human pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1) and methods of making thereof202411,780,914PACAP antibodies and uses thereof202311,248,043Methods for treating a headache condition using anti-human PAC1 antibodies or antigen-binding fragments thereof2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2024Patents assigned to AMGEN INC (6)· patent assignee history
2022–2024Based in US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| AMGEN INC | 6 | 2022–2024 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 6 | 2022–2024 |